title: [Mechanism and drug treatment of atherothrombosis].
abstract: The better understanding of processes and consequences in atherothrombosis has changed recent cardiovascular medicine fundamentally. The importance of multiple-action combined medical drug therapy has been obviously outlined by the discovery of the simultaneous, multiplex, multilocular merit of atherothrombosis. Recently, the detrimental effect of selective cyclooxygenase-2 inhibitors has been shown on vascular integrity. Certain lipid lowering drugs with pleiotropic and lipid effects have become a treatment option of the acute phase of atherothrombosis. Similarly to statins, combined antiplatelet drug strategy has been proven effective in any form of plaque rupture of coronary arteries, with either spontaneous or intervention-related origin (every appearance of acute coronary syndromes, percutaneous angioplasty). Occlusive forms of atherothrombosis need urgent reperfusion/revascularisation technics, as fibrinolytic therapy, endovascular or rarely traditional surgery.
authors.affiliation: Országos Gyógyintézeti Központ.
authors.forename: Róbert Gábor
authors.initials: RG
authors.lastname: Kiss
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000503:physiopathology*; D001241:Aspirin / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism; D019013:CD40 Antigens / Q000378:metabolism; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000188:drug therapy* / Q000503:physiopathology*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D019013:CD40 Antigens; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D006493:Heparin; D002097:C-Reactive Protein; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin